XML 35 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1

Other Assets

12 Months Ended

Dec. 31, 2024

Other Assets [Abstract]

Other assets

12. Other assets

	Year ended December 31,
	2024			2023
	$000s			$000s
Prepayments		13,124			10,385
VAT receivable		1,540			1,245
Total other current assets		14,664			11,630
Deposits for properties		356			362
Prepayments		3,234			3,284
Other long-term assets		3,590			3,646

At December 31, 2024 and 2023, the largest component of prepayments are prepaid third party costs for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies which fluctuate based on timing of payments and related expense.

Included within prepayments at December 31, 2024 and 2023 is $11.0 million and $8.7 million respectively, are expenditures relating to research and development.

X

- References

No definition available.

+ Details

Name:	us-gaap_OtherAssetsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherAssetsDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration